|
|||||
|
|
Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy |
|
| Authors: | Kaspar Broch Ida S Leren Jørg Saberniak Thor Ueland Thor Edvardsen Lars Gullestad |
| Institution: | 1. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway;2. Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway;3. Center for Cardiological Innovation, Oslo University Hospital, Rikshospitalet, Oslo, Norway;4. Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway;5. Faculty of Medicine, University of Oslo, Oslo, Norway |
| Abstract: | Purpose: Diagnostic and prognostic evaluation remains challenging in arrhythmogenic right ventricular cardiomyopathy (ARVC). We measured plasma concentration of soluble ST2 (sST2) and assessed its association with right ventricular (RV) function and ventricular arrhythmias in patients with ARVC. Methods: We included patients with ARVC and genotype positive relatives. Soluble ST2 was determined by ELISA. We assessed myocardial function by echocardiography including strain by speckle tracking technique. Results: We included 44 subjects (age 41?±?15 years, 21 (48%) female). Soluble ST2 was associated with RV global strain (r?=?0.44; p?=?0.008), as well as with left ventricular (LV) function. Plasma levels of sST2 were higher in patients with ventricular arrhythmias than in patients without ventricular arrhythmias (35?±?13?ng/mL vs. 26?±?7?ng/mL, p?=?0.009). The association between sST2 and ventricular arrhythmias remained significant even after adjusting for RV function (Wald?=?5.2; p?=?0.02). Conclusions: Soluble ST2 is associated with RV and LV function in patients with ARVC. Soluble ST2 may aid in the determination of disease severity in ARVC. |
| Keywords: | Arrhythmogenic right ventricular cardiomyopathy ST2 biomarker right ventricular function ventricular arrhythmia |